Zila’s OraTest Oral Cancer Screen Lags At CDER; ZTC Clears Premarket Hurdle
This article was originally published in The Gray Sheet
Executive Summary
Zila Medical's strategy of seeking an adjunctive claim for its ZTC tolonium chloride compound enabled a relatively quick device review, CEO Douglas Burkett said in a Feb. 7 conference call